<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085184</url>
  </required_header>
  <id_info>
    <org_study_id>KUP-UI018-103</org_study_id>
    <nct_id>NCT05085184</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and PK of UI018</brief_title>
  <official_title>A Randomized, Open, Single-dose, 2x2x4 Replicate Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of UIC201806 and UIC201602 or Administration of UI018 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea United Pharm. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea United Pharm. Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Study is to evaluate the safety and pharmacokinetics of a fixed dose combination&#xD;
      formulation and co-administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2021</start_date>
  <completion_date type="Anticipated">September 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum concentration(Cmax)</measure>
    <time_frame>0 to 96 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve(AUC)</measure>
    <time_frame>0 to 96 hrs</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Hyperlipemia, Mixed</condition>
  <arm_group>
    <arm_group_label>UI018</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>UIC201806 and UIC201602</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>administration of UI018</intervention_name>
    <description>Test</description>
    <arm_group_label>UI018</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>co-administration of UIC201806 and UIC201602</intervention_name>
    <description>Reference</description>
    <arm_group_label>UIC201806 and UIC201602</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects between the ages of 19 and 45 years at screening&#xD;
&#xD;
          -  Subjects whose body weight over 55 kg and ranged Â± 20% of calculated Ideal body&#xD;
             Weight(IBW) [ IBW (kg) = (height(cm) - 100) x 0.9 ]&#xD;
&#xD;
          -  Subjects able to read and understand a written informed consent, and willing to decide&#xD;
             to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Injin Jang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Injin Jang, Dr.</last_name>
    <phone>02-741-4221</phone>
    <email>snuh-ctc@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Injin Jang, M.D., Ph.D</last_name>
      <phone>+82-2-7102-6476</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Juyoung Khwarg</last_name>
      <phone>+82-2-7102-6476</phone>
      <email>juyoungkhwarg@snu.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Injin Jang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type V</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

